Skip to main content
Erschienen in:

04.10.2018 | Original Paper

The Depression Treatment Cascade: Disparities by Alcohol Use, Drug Use, and Panic Symptoms Among Patients in Routine HIV Care in the United States

verfasst von: Bethany L. DiPrete, Brian W. Pence, Angela M. Bengtson, Richard D. Moore, David J. Grelotti, Conall O’Cleirigh, Riddhi Modi, Bradley N. Gaynes

Erschienen in: AIDS and Behavior | Ausgabe 3/2019

Einloggen, um Zugang zu erhalten

Abstract

Little is known about disparities in depression prevalence, treatment, and remission by psychiatric comorbidities and substance use among persons living with HIV (PLWH). We conducted a cross-sectional analysis in a large cohort of PLWH in routine care and analyzed conditional probabilities of having an indication for depression treatment, receiving treatment, receiving indicated treatment adjustments, and achieving remission, stratified by alcohol use, illicit drug use, and panic symptoms. Overall, 34.7% (95% CI 33.9–35.5%) of participants had an indication for depression treatment and of these, 55.3% (53.8–56.8%) were receiving antidepressants. Among patients receiving antidepressants, 33.0% (31.1–34.9%) had evidence of remitted depression. In a subsample of sites with antidepressant dosage data, only 8.8% (6.7–11.5%) of patients received an indicated treatment adjustment. Current drug users (45.8%, 95% CI 43.6–48.1%) and patients reporting full symptoms of panic disorder (75.0%, 95% CI 72.9–77.1%) were most likely to have an indication for antidepressant treatment, least likely to receive treatment given an indication (current drug use: 47.6%, 95% CI 44.3–51.0%; full panic symptoms: 50.8%, 95% CI 48.0–53.6%), or have evidence of remitted depression when treated (22.3%, 95% CI 18.5–26.6%; and 7.3%, 95% CI 5.5–9.6%, respectively). In a multivariable model, drug use and panic symptoms were independently associated with poorer outcomes along the depression treatment cascade. Few differences were evident by alcohol use. Current drug users were most likely to have an indication for depression treatment, but were least likely to be receiving treatment or to have remitted depression. These same disparities were even more starkly evident among patients with co-occurring symptoms of panic disorder compared to those without. Achieving improvements in the depression treatment cascade will likely require attention to substance use and psychiatric comorbidities.
Literatur
1.
Zurück zum Zitat Pence BW, Miller WC, Whetten K, Eron JJ, Gaynes BN. Prevalence of DSM-IV-defined mood, anxiety, and substance use disorders in an HIV clinic in the Southeastern United States. JAIDS. 2006;42(3):298–306.PubMed Pence BW, Miller WC, Whetten K, Eron JJ, Gaynes BN. Prevalence of DSM-IV-defined mood, anxiety, and substance use disorders in an HIV clinic in the Southeastern United States. JAIDS. 2006;42(3):298–306.PubMed
2.
Zurück zum Zitat Bing EG, Burnam MA, Longshore D, et al. Psychiatric disorders and drug use among human immunodeficiency virus-infected adults in the United States. Arch Gen Psychiatry. 2001;58(8):721–8.CrossRef Bing EG, Burnam MA, Longshore D, et al. Psychiatric disorders and drug use among human immunodeficiency virus-infected adults in the United States. Arch Gen Psychiatry. 2001;58(8):721–8.CrossRef
3.
Zurück zum Zitat Ciesla JA, Roberts JE. Meta-analysis of the relationship between HIV infection and risk for depressive disorders. AJP. 2001;158(5):725–30.CrossRef Ciesla JA, Roberts JE. Meta-analysis of the relationship between HIV infection and risk for depressive disorders. AJP. 2001;158(5):725–30.CrossRef
4.
Zurück zum Zitat Orlando M, Burnam MA, Beckman R, et al. Re-estimating the prevalence of psychiatric disorders in a nationally representative sample of persons receiving care for HIV: results from the HIV cost and services utilization study. Int J Methods Psychiatr Res. 2002;11(2):75–82.CrossRef Orlando M, Burnam MA, Beckman R, et al. Re-estimating the prevalence of psychiatric disorders in a nationally representative sample of persons receiving care for HIV: results from the HIV cost and services utilization study. Int J Methods Psychiatr Res. 2002;11(2):75–82.CrossRef
5.
Zurück zum Zitat Schumacher JE, McCullumsmith C, Mugavero MJ, et al. Routine depression screening in an HIV clinic cohort identifies patients with complex psychiatric co-morbidities who show significant response to treatment. AIDS Behav. 2013;17(8):2781–91.CrossRef Schumacher JE, McCullumsmith C, Mugavero MJ, et al. Routine depression screening in an HIV clinic cohort identifies patients with complex psychiatric co-morbidities who show significant response to treatment. AIDS Behav. 2013;17(8):2781–91.CrossRef
6.
Zurück zum Zitat Tegger MK, Crane HM, Tapia KA, Uldall KK, Holte SE, Kitahata MM. The effect of mental illness, substance use, and treatment for depression on the initiation of highly active antiretroviral therapy among HIV-infected individuals. AIDS Patient Care STDS. 2008;22(3):233–43.CrossRef Tegger MK, Crane HM, Tapia KA, Uldall KK, Holte SE, Kitahata MM. The effect of mental illness, substance use, and treatment for depression on the initiation of highly active antiretroviral therapy among HIV-infected individuals. AIDS Patient Care STDS. 2008;22(3):233–43.CrossRef
7.
Zurück zum Zitat Mugavero M, Ostermann J, Whetten K, et al. Barriers to antiretroviral adherence: the importance of depression, abuse, and other traumatic events. AIDS Patient Care STDs. 2006;20(6):418–28.CrossRef Mugavero M, Ostermann J, Whetten K, et al. Barriers to antiretroviral adherence: the importance of depression, abuse, and other traumatic events. AIDS Patient Care STDs. 2006;20(6):418–28.CrossRef
9.
Zurück zum Zitat Zuniga JA, Yoo-Jeong M, Dai T, Guo Y, Waldrop-Valverde D. The role of depression in retention in care for persons living with HIV. AIDS Patient Care STDs. 2015;30(1):34–8.CrossRef Zuniga JA, Yoo-Jeong M, Dai T, Guo Y, Waldrop-Valverde D. The role of depression in retention in care for persons living with HIV. AIDS Patient Care STDs. 2015;30(1):34–8.CrossRef
10.
Zurück zum Zitat Pence BW, Miller WC, Gaynes BN, Eron JJ. Psychiatric illness and virologic response in patients initiating highly active antiretroviral therapy. JAIDS. 2007;44(2):159–66.PubMed Pence BW, Miller WC, Gaynes BN, Eron JJ. Psychiatric illness and virologic response in patients initiating highly active antiretroviral therapy. JAIDS. 2007;44(2):159–66.PubMed
11.
Zurück zum Zitat Todd JV, Cole SR, Pence BW, et al. Effects of antiretroviral therapy and depressive symptoms on all-cause mortality among HIV-infected women. Am J Epidemiol. 2017;185(10):869–78.CrossRef Todd JV, Cole SR, Pence BW, et al. Effects of antiretroviral therapy and depressive symptoms on all-cause mortality among HIV-infected women. Am J Epidemiol. 2017;185(10):869–78.CrossRef
12.
Zurück zum Zitat Mugavero MJ, Pence BW, Whetten K, et al. Predictors of AIDS-related morbidity and mortality in a Southern U.S. Cohort. AIDS Patient Care STDs. 2007;21(9):681–90.CrossRef Mugavero MJ, Pence BW, Whetten K, et al. Predictors of AIDS-related morbidity and mortality in a Southern U.S. Cohort. AIDS Patient Care STDs. 2007;21(9):681–90.CrossRef
13.
Zurück zum Zitat Pence BW, O’Donnell JK, Gaynes BN. Falling through the cracks: the gaps between depression prevalence, diagnosis, treatment, and response in HIV care. AIDS. 2012;26(5):656–8.CrossRef Pence BW, O’Donnell JK, Gaynes BN. Falling through the cracks: the gaps between depression prevalence, diagnosis, treatment, and response in HIV care. AIDS. 2012;26(5):656–8.CrossRef
14.
Zurück zum Zitat Pence BW, Gaynes BN, Adams JL, et al. The effect of antidepressant treatment on HIV and depression outcomes: results from a randomized trial. AIDS. 2015;29(15):1975–86.CrossRef Pence BW, Gaynes BN, Adams JL, et al. The effect of antidepressant treatment on HIV and depression outcomes: results from a randomized trial. AIDS. 2015;29(15):1975–86.CrossRef
15.
Zurück zum Zitat Himelhoch S, Medoff DR. Efficacy of antidepressant medication among HIV-positive individuals with depression: a systematic review and meta-analysis. AIDS Patient Care STDs. 2005;19(12):813–22.CrossRef Himelhoch S, Medoff DR. Efficacy of antidepressant medication among HIV-positive individuals with depression: a systematic review and meta-analysis. AIDS Patient Care STDs. 2005;19(12):813–22.CrossRef
16.
Zurück zum Zitat Himelhoch S, Medoff DR, Oyeniyi G. Efficacy of group psychotherapy to reduce depressive symptoms among HIV-infected individuals: a systematic review and meta-analysis. AIDS Patient Care STDS. 2007;21(10):732–9.CrossRef Himelhoch S, Medoff DR, Oyeniyi G. Efficacy of group psychotherapy to reduce depressive symptoms among HIV-infected individuals: a systematic review and meta-analysis. AIDS Patient Care STDS. 2007;21(10):732–9.CrossRef
17.
Zurück zum Zitat Sin NL, DiMatteo MR. Depression treatment enhances adherence to antiretroviral therapy: a meta-analysis. Ann Behav Med. 2014;47(3):259–69.CrossRef Sin NL, DiMatteo MR. Depression treatment enhances adherence to antiretroviral therapy: a meta-analysis. Ann Behav Med. 2014;47(3):259–69.CrossRef
18.
Zurück zum Zitat Springer SA, Dushaj A, Azar MM. The impact of DSM-IV mental disorders on adherence to combination antiretroviral therapy among adult persons living with HIV/AIDS: a systematic review. AIDS Behav. 2012;16(8):2119–43.CrossRef Springer SA, Dushaj A, Azar MM. The impact of DSM-IV mental disorders on adherence to combination antiretroviral therapy among adult persons living with HIV/AIDS: a systematic review. AIDS Behav. 2012;16(8):2119–43.CrossRef
19.
Zurück zum Zitat Tsai AC, Karasic DH, Hammer GP, et al. Directly observed antidepressant medication treatment and HIV outcomes among homeless and marginally housed HIV-positive adults: a randomized controlled trial. Am J Public Health. 2013;103(2):308–15.CrossRef Tsai AC, Karasic DH, Hammer GP, et al. Directly observed antidepressant medication treatment and HIV outcomes among homeless and marginally housed HIV-positive adults: a randomized controlled trial. Am J Public Health. 2013;103(2):308–15.CrossRef
20.
Zurück zum Zitat Pyne JM, Fortney JC, Curran GM, et al. Effectiveness of collaborative care for depression in human immunodeficiency virus clinics. Arch Intern Med. 2011;171(1):23–31.PubMed Pyne JM, Fortney JC, Curran GM, et al. Effectiveness of collaborative care for depression in human immunodeficiency virus clinics. Arch Intern Med. 2011;171(1):23–31.PubMed
21.
Zurück zum Zitat O’Cleirigh C, Magidson JF, Skeer MR, Mayer KH, Safren SA. Prevalence of psychiatric and substance abuse symptomatology among HIV-infected gay and bisexual men in HIV primary care. Psychosomatics. 2015;56(5):470–8.CrossRef O’Cleirigh C, Magidson JF, Skeer MR, Mayer KH, Safren SA. Prevalence of psychiatric and substance abuse symptomatology among HIV-infected gay and bisexual men in HIV primary care. Psychosomatics. 2015;56(5):470–8.CrossRef
22.
Zurück zum Zitat Cholera R, Pence BW, Bengtson AM, et al. Mind the gap: gaps in antidepressant treatment, treatment adjustments, and outcomes among patients in routine HIV care in a multisite U.S. Clinical Cohort. PLoS ONE. 2017;12(1):e0166435.CrossRef Cholera R, Pence BW, Bengtson AM, et al. Mind the gap: gaps in antidepressant treatment, treatment adjustments, and outcomes among patients in routine HIV care in a multisite U.S. Clinical Cohort. PLoS ONE. 2017;12(1):e0166435.CrossRef
23.
Zurück zum Zitat Gardner EM, McLees MP, Steiner JF, Del Rio C, Burman WJ. The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clin Infect Dis. 2011;52(6):793–800.CrossRef Gardner EM, McLees MP, Steiner JF, Del Rio C, Burman WJ. The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clin Infect Dis. 2011;52(6):793–800.CrossRef
24.
Zurück zum Zitat Kay ES, Batey DS, Mugavero MJ. The HIV treatment cascade and care continuum: updates, goals, and recommendations for the future. AIDS Res Ther. 2016;13:35.CrossRef Kay ES, Batey DS, Mugavero MJ. The HIV treatment cascade and care continuum: updates, goals, and recommendations for the future. AIDS Res Ther. 2016;13:35.CrossRef
25.
Zurück zum Zitat Mugavero MJ, Amico KR, Horn T, Thompson MA. The state of engagement in HIV care in the United States: from cascade to continuum to control. Clin Infect Dis. 2013;57(8):1164–71.CrossRef Mugavero MJ, Amico KR, Horn T, Thompson MA. The state of engagement in HIV care in the United States: from cascade to continuum to control. Clin Infect Dis. 2013;57(8):1164–71.CrossRef
26.
Zurück zum Zitat Brandt C, Zvolensky MJ, Woods SP, Gonzalez A, Safren SA, O’Cleirigh CM. Anxiety symptoms and disorders among adults living with HIV and AIDS: a critical review and integrative synthesis of the empirical literature. Clin Psychol Rev. 2017;51:164–84.CrossRef Brandt C, Zvolensky MJ, Woods SP, Gonzalez A, Safren SA, O’Cleirigh CM. Anxiety symptoms and disorders among adults living with HIV and AIDS: a critical review and integrative synthesis of the empirical literature. Clin Psychol Rev. 2017;51:164–84.CrossRef
27.
Zurück zum Zitat Chander G, Lau B, Moore RD. Hazardous alcohol use: a risk factor for non-adherence and lack of suppression in HIV infection. J Acquir Immune Defic Syndr. 2006;43(4):411–7.CrossRef Chander G, Lau B, Moore RD. Hazardous alcohol use: a risk factor for non-adherence and lack of suppression in HIV infection. J Acquir Immune Defic Syndr. 2006;43(4):411–7.CrossRef
28.
Zurück zum Zitat Gaynes BN, Pence BW, Eron JJ, Miller WC. Prevalence and comorbidity of psychiatric diagnoses based on reference standard in an HIV+ patient population. Psychosom Med. 2008;70(4):505–11.CrossRef Gaynes BN, Pence BW, Eron JJ, Miller WC. Prevalence and comorbidity of psychiatric diagnoses based on reference standard in an HIV+ patient population. Psychosom Med. 2008;70(4):505–11.CrossRef
29.
Zurück zum Zitat Lucas GM, Gebo KA, Chaisson RE, Moore RD. Longitudinal assessment of the effects of drug and alcohol abuse on HIV-1 treatment outcomes in an urban clinic. AIDS. 2002;16(5):767–74.CrossRef Lucas GM, Gebo KA, Chaisson RE, Moore RD. Longitudinal assessment of the effects of drug and alcohol abuse on HIV-1 treatment outcomes in an urban clinic. AIDS. 2002;16(5):767–74.CrossRef
30.
Zurück zum Zitat Hahn JA, Samet JH. Alcohol and HIV disease progression: weighing the evidence. Curr HIV/AIDS Rep. 2010;7(4):226–33.CrossRef Hahn JA, Samet JH. Alcohol and HIV disease progression: weighing the evidence. Curr HIV/AIDS Rep. 2010;7(4):226–33.CrossRef
31.
Zurück zum Zitat Nolan S, Walley AY, Heeren TC, et al. HIV-infected individuals who use alcohol and other drugs, and virologic suppression. AIDS Care. 2017;29(9):1129–36.CrossRef Nolan S, Walley AY, Heeren TC, et al. HIV-infected individuals who use alcohol and other drugs, and virologic suppression. AIDS Care. 2017;29(9):1129–36.CrossRef
32.
Zurück zum Zitat Gaynes BN, O’Donnell J, Nelson E, et al. Psychiatric comorbidity in depressed HIV-infected individuals: common and clinically consequential. Gen Hosp Psychiatry. 2015;37(4):277–82.CrossRef Gaynes BN, O’Donnell J, Nelson E, et al. Psychiatric comorbidity in depressed HIV-infected individuals: common and clinically consequential. Gen Hosp Psychiatry. 2015;37(4):277–82.CrossRef
33.
Zurück zum Zitat Israelski DM, Prentiss DE, Lubega S, et al. Psychiatric co-morbidity in vulnerable populations receiving primary care for HIV/AIDS. AIDS Care. 2007;19(2):220–5.CrossRef Israelski DM, Prentiss DE, Lubega S, et al. Psychiatric co-morbidity in vulnerable populations receiving primary care for HIV/AIDS. AIDS Care. 2007;19(2):220–5.CrossRef
34.
Zurück zum Zitat Sowa NA, Bengtson A, Gaynes BN, Pence BW. Predictors of depression recovery in HIV-infected individuals managed through measurement-based care in infectious disease clinics. J Affect Disord. 2016;192:153–61.CrossRef Sowa NA, Bengtson A, Gaynes BN, Pence BW. Predictors of depression recovery in HIV-infected individuals managed through measurement-based care in infectious disease clinics. J Affect Disord. 2016;192:153–61.CrossRef
35.
Zurück zum Zitat Kitahata MM, Rodriguez B, Haubrich R, et al. Cohort profile: the Centers for AIDS Research Network of Integrated Clinical Systems. Int J Epidemiol. 2008;37(5):948–55.CrossRef Kitahata MM, Rodriguez B, Haubrich R, et al. Cohort profile: the Centers for AIDS Research Network of Integrated Clinical Systems. Int J Epidemiol. 2008;37(5):948–55.CrossRef
36.
Zurück zum Zitat Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16(9):606–13.CrossRef Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16(9):606–13.CrossRef
37.
Zurück zum Zitat Crane PK, Gibbons LE, Willig JH, et al. Measuring depression levels in HIV-infected patients as part of routine clinical care using the 9-item patient health questionnaire (PHQ-9). AIDS Care. 2010;22(7):874–85.CrossRef Crane PK, Gibbons LE, Willig JH, et al. Measuring depression levels in HIV-infected patients as part of routine clinical care using the 9-item patient health questionnaire (PHQ-9). AIDS Care. 2010;22(7):874–85.CrossRef
38.
Zurück zum Zitat Kroenke K, Spitzer RL. The PHQ-9: a new depression diagnostic and severity measure. Psychiatr Ann. 2002;32(9):509–15.CrossRef Kroenke K, Spitzer RL. The PHQ-9: a new depression diagnostic and severity measure. Psychiatr Ann. 2002;32(9):509–15.CrossRef
39.
Zurück zum Zitat Saunders JB, Aasland OG, Babor TF, de la Fuente JR, Grant M. Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on early detection of persons with harmful alcohol consumption-II. Addiction. 1993;88(6):791–804.CrossRef Saunders JB, Aasland OG, Babor TF, de la Fuente JR, Grant M. Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on early detection of persons with harmful alcohol consumption-II. Addiction. 1993;88(6):791–804.CrossRef
40.
Zurück zum Zitat Humeniuk R, Ali R, Babor TF, et al. Validation of the alcohol, smoking and substance involvement screening test (ASSIST). Addiction. 2008;103(6):1039–47.CrossRef Humeniuk R, Ali R, Babor TF, et al. Validation of the alcohol, smoking and substance involvement screening test (ASSIST). Addiction. 2008;103(6):1039–47.CrossRef
41.
Zurück zum Zitat WHO Assist Working Group. The Alcohol, smoking and substance involvement screening test (ASSIST): development, reliability and feasibility. Addiction. 2002;97(9):1183–94.CrossRef WHO Assist Working Group. The Alcohol, smoking and substance involvement screening test (ASSIST): development, reliability and feasibility. Addiction. 2002;97(9):1183–94.CrossRef
42.
Zurück zum Zitat Spitzer RL, Kroenke K, Williams JB. Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary Care Evaluation of Mental Disorders. Patient Health Questionnaire. JAMA. 1999;282(18):1737–44.CrossRef Spitzer RL, Kroenke K, Williams JB. Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary Care Evaluation of Mental Disorders. Patient Health Questionnaire. JAMA. 1999;282(18):1737–44.CrossRef
43.
Zurück zum Zitat Asch SM, Kilbourne AM, Gifford AL, et al. Underdiagnosis of depression in HIV: who are we missing? J Gen Intern Med. 2003;18(6):450–60.CrossRef Asch SM, Kilbourne AM, Gifford AL, et al. Underdiagnosis of depression in HIV: who are we missing? J Gen Intern Med. 2003;18(6):450–60.CrossRef
44.
Zurück zum Zitat Bengtson AM, Pence BW, Crane HM, et al. Disparities in depressive symptoms and antidepressant treatment by gender and race/ethnicity among people living with HIV in the United States. PLoS ONE. 2016;11(8):e0160738.CrossRef Bengtson AM, Pence BW, Crane HM, et al. Disparities in depressive symptoms and antidepressant treatment by gender and race/ethnicity among people living with HIV in the United States. PLoS ONE. 2016;11(8):e0160738.CrossRef
45.
Zurück zum Zitat Bakker A, van Balkom AJ, Spinhoven P. SSRIs vs. TCAs in the treatment of panic disorder: a meta-analysis. Acta Psychiatr Scand. 2002;106(3):163–7.CrossRef Bakker A, van Balkom AJ, Spinhoven P. SSRIs vs. TCAs in the treatment of panic disorder: a meta-analysis. Acta Psychiatr Scand. 2002;106(3):163–7.CrossRef
46.
Zurück zum Zitat Grelotti DJ, Hammer GP, Dilley JW, et al. Does substance use compromise depression treatment in persons with HIV? Findings from a randomized controlled trial. AIDS Care. 2017;29(3):273–9.CrossRef Grelotti DJ, Hammer GP, Dilley JW, et al. Does substance use compromise depression treatment in persons with HIV? Findings from a randomized controlled trial. AIDS Care. 2017;29(3):273–9.CrossRef
Metadaten
Titel
The Depression Treatment Cascade: Disparities by Alcohol Use, Drug Use, and Panic Symptoms Among Patients in Routine HIV Care in the United States
verfasst von
Bethany L. DiPrete
Brian W. Pence
Angela M. Bengtson
Richard D. Moore
David J. Grelotti
Conall O’Cleirigh
Riddhi Modi
Bradley N. Gaynes
Publikationsdatum
04.10.2018
Verlag
Springer US
Erschienen in
AIDS and Behavior / Ausgabe 3/2019
Print ISSN: 1090-7165
Elektronische ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-018-2282-3

Weitere Artikel der Ausgabe 3/2019

AIDS and Behavior 3/2019 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Neu im Fachgebiet Innere Medizin

Tisotumab-Vedotin verlängert Überleben nach Zervixkarzinom-Rezidiv

13.07.2024 Zervixkarzinom Nachrichten

Für Frauen mit rezidiviertem oder metastasiertem Zervixkarzinom und Versagen der Erstlinientherapie zeichnet sich eine Verbesserung der Behandlungsoptionen ab: Mit dem Antikörper-Wirkstoff-Konjugat Tisotumab-Vedotin überleben sie zwei Monate länger als mit einer Chemotherapie.

Aggressive Blutdrucksenkung bei Risikopersonen?

12.07.2024 Arterielle Hypertonie Nachrichten

Geht es nach einer aktuellen chinesischen Studie, ist die Einstellung des systolischen Blutdrucks bei Risikopersonen auf Werte unter 120 mmHg mit weniger kardiovaskulären Ereignissen assoziiert als die Senkung auf Werte unter 140 mmHg.

Was das Überwachen von Risikopersonen für Pankreaskrebs bringt

12.07.2024 Pankreaskarzinom Nachrichten

Programme zur Überwachung von Hochrisikokandidaten für duktales Adenokarzinom des Pankreas führen womöglich zu früherer Diagnose. Ob sich das auch in einem Überlebensvorteil niederschlägt, hat eine Studie getestet.

Ältere Männer mit kutaner Vaskulitis? Das könnte VEXAS sein

12.07.2024 VEXAS-Syndrom Nachrichten

Hautmanifestationen wie eine leukozytoklastische Vaskulitis oder eine neutrophile Dermatose sind oft die ersten und auffälligsten Zeichen eines VEXAS-Syndroms. Dermatologen kommt daher eine entscheidende Bedeutung bei der Diagnose der seltenen Krankheit zu.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.